Dmitry Balyasny’s Esperion Therapeutics ESPR Stock Holding History

Dmitry Balyasny’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-100,000	Closed	-$3.72M	–	1429
2020 Q3	$3.72M	Buy	+100,000	New	+$3.96M	0.03%	684
2020 Q2	–	Sell	-50,000	Closed	-$1.58M	–	1229
2020 Q1	$1.58M	Sell	50,000 -75,000	-60%	-$3.96M	0.02%	660
2019 Q4	$7.45M	Buy	+125,000	New	+$5.62M	0.04%	501
2019 Q1	–	Sell	-108,000	Closed	-$4.97M	–	1453
2018 Q4	$4.97M	Buy	+108,000	New	+$5.2M	0.04%	507
2017 Q3	–	Sell	-140,000	Closed	-$6.48M	–	1929
2017 Q2	$6.48M	Buy	+140,000	New	+$5.15M	0.03%	680

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Dmitry Balyasny's ESPR Position: Q2 2026 in Review

Dmitry Balyasny opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 4,654,778 shares worth $14.7M. The stake represents 0.02% of the portfolio and ranks #878 among its holdings. This is a return to the name: Dmitry Balyasny previously reported a position in ESPR as recently as Q3 2025.

Dmitry Balyasny first reported a position in ESPR in Q1 2017 and has held it in 21 quarters since. The position peaked at $26.5M in Q4 2017. 189 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

Dmitry Balyasny held 4,654,778 shares of Esperion Therapeutics worth $14.7M as of Q2 2026.
Esperion Therapeutics was a new Dmitry Balyasny position in Q2 2026.
Esperion Therapeutics made up 0.02% of Dmitry Balyasny's portfolio in Q2 2026, its #878 holding.
Dmitry Balyasny first reported a position in Esperion Therapeutics in Q1 2017 and has held it in 21 quarters since.
Dmitry Balyasny's Esperion Therapeutics position peaked at $26.5M in Q4 2017.
189 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.